marketcap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
PerkinElmer Financial Ratios 2011-2025 | PKI
Annual Financial Ratios PerkinElmer
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
52.3 | 22.3 | 15.2 | 150.2 | - | 47.5 | 40.7 | 24.9 | 25.2 | - | 31.4 | 28.7 | 351.8 | 22.4 |
P/S |
5.1 | 5.6 | 3.8 | 22.3 | - | 3.7 | 3.5 | 2.8 | 2.5 | - | 2.2 | 2.2 | 1.4 | 5.0 |
EPS |
2.2 | 5.6 | 8.1 | 1.1 | - | 2.1 | 2.1 | 2.7 | 1.9 | - | 1.4 | 1.5 | 0.6 | 3.3 |
EV (Enterprise Value) |
17.7 B | 20.2 B | 21.6 B | 23 B | - | 14.3 B | 12.9 B | 7.74 B | 7.17 B | - | 6.86 B | 6.57 B | 4.53 B | 9.47 B |
EBITDA per Share |
6.31 | 5.87 | 13.5 | 3.56 | - | 4.88 | 4.68 | 3.65 | 3.17 | - | 2.91 | 3.08 | 1.79 | 0.811 |
EV/EBITDA |
18.8 | - | 23.4 | 22.0 | 16.3 | 17.2 | - | 17.8 | 16.1 | 17.4 | 32.1 | |||
PEG |
- | - | -10.23 | -2.17 | 1.86 | 0.73 | - | -5.31 | 0.2 | -3.59 | 0.07 | |||
P/B |
1.8 | 2.0 | 2.0 | 5.1 | - | 3.8 | 3.7 | 2.7 | 2.5 | - | 2.4 | 2.4 | 1.5 | 4.5 |
P/CF |
22.5 | 169.1 | 10.2 | 21.5 | - | 38.3 | 44.5 | 18.3 | 20.7 | - | 19.6 | 40.1 | 13.9 | 65.8 |
ROE % |
3.53 | 8.80 | 13.21 | 3.42 | - | 8.09 | 9.20 | 10.88 | 10.07 | - | 7.73 | 8.38 | 0.42 | 19.93 |
ROA % |
2.18 | 5.11 | 6.29 | 1.60 | - | 3.48 | 3.98 | 5.48 | 5.10 | - | 3.82 | 4.24 | 0.20 | 11.96 |
ROCE % |
4.52 | 3.82 | 17.62 | 5.24 | - | 5.66 | 6.47 | 8.17 | 6.96 | - | 5.96 | 6.50 | 2.82 | 6.65 |
Current Ratio |
2.6 | 2.4 | 1.9 | 1.9 | - | 1.8 | 1.6 | 2.0 | 1.8 | - | 1.8 | 1.7 | 1.4 | 2.1 |
DSO |
87.6 | 92.9 | 91.3 | 249.5 | - | 91.8 | 83.1 | 73.4 | 72.0 | - | 76.8 | 79.2 | 77.9 | 76.4 |
DIO |
- | - | - | - | - | 87.6 | 85.9 | 81.8 | 83.0 | - | 84.5 | 80.1 | 82.1 | 80.0 |
DPO |
- | - | - | - | - | 57.9 | 56.1 | 55.7 | 45.1 | - | 51.5 | 51.3 | 59.0 | 62.1 |
Operating Cycle |
87.6 | 92.9 | 91.3 | 249.5 | - | 179.4 | 169.1 | 155.3 | 155.0 | - | 161.3 | 159.3 | 160.0 | 156.4 |
Cash Conversion Cycle |
87.6 | 92.9 | 91.3 | 249.5 | - | 121.5 | 112.9 | 99.6 | 109.9 | - | 109.8 | 108.0 | 100.9 | 94.3 |
All numbers in USD currency
Quarterly Financial Ratios PerkinElmer
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
0.4 | 0.46 | 0.35 | - | 0.77 | 0.45 | 0.21 | - | 0.08 | 0.28 | 4.51 | - | 0.68 | 1.42 | 1.4 | 3.4 | 1.12 | 2.2 | 3.39 | - | 1.58 | 1.23 | 0.3 | 0.58 | 0.53 | 0.62 | 0.32 | 0.64 | 0.69 | 0.58 | 0.24 | -0.37 | 0.83 | 1.86 | 0.35 | 0.61 | 0.53 | 0.59 | 0.43 | - | 0.49 | 0.43 | 0.36 | 0.27 | 0.38 | 0.45 | 0.3 | 0.6 | 0.36 | 0.25 | 0.28 | -0.14 | 0.26 | 0.3 | 0.2 | 2.52 | 0.32 | 0.26 | 0.22 |
EBITDA per Share |
0.87 | 0.92 | 1.41 | - | 0.95 | 0.83 | 1.23 | - | 1.29 | 1.36 | 1.47 | - | 1.6 | 2.59 | 2.94 | 4.55 | 3.43 | 4.27 | 4.8 | - | 3.85 | 2.66 | 0.95 | 1.24 | 2.13 | 1.76 | 0.94 | 1.05 | 1.93 | 1.6 | 0.77 | 0.85 | 1.4 | 1.13 | 0.68 | 0.69 | 1.38 | 1.07 | 0.78 | - | 1.34 | 1.03 | 0.67 | 0.27 | 1.29 | 1.13 | 0.72 | 0.83 | 1.37 | 0.92 | 0.59 | -0.27 | 1.21 | 1 | 0.6 | 0.42 | 1.02 | 0.8 | 0.57 |
ROE % |
3.09 | 3.65 | 3.64 | 2.23 | 2.35 | 1.28 | 1.03 | 7.66 | 8.87 | 9.96 | 12.00 | 6.17 | 16.35 | 16.98 | 20.28 | 27.30 | 22.58 | 26.21 | 25.03 | 11.31 | 13.60 | 10.22 | 8.05 | 8.09 | 8.55 | 9.43 | 9.46 | 9.20 | 4.80 | 5.48 | 11.16 | 11.69 | 16.57 | 15.65 | 10.56 | 11.33 | 10.77 | 10.72 | 9.97 | 6.94 | 8.45 | 7.85 | 8.01 | 7.73 | 9.57 | 9.52 | 8.44 | 8.38 | 4.21 | 3.72 | 4.06 | 3.61 | 19.64 | 19.99 | 19.78 | 19.92 | 1.88 | 1.52 | 1.31 |
ROA % |
1.90 | 2.26 | 2.23 | 1.35 | 1.42 | 0.75 | 0.59 | 4.21 | 4.83 | 5.38 | 6.39 | 3.07 | 7.85 | 8.09 | 9.64 | 12.78 | 10.57 | 12.29 | 11.54 | 5.17 | 6.15 | 4.48 | 3.47 | 3.48 | 3.69 | 4.07 | 4.09 | 3.98 | 2.11 | 2.33 | 4.61 | 4.80 | 7.12 | 6.97 | 5.14 | 5.64 | 5.36 | 5.37 | 5.05 | 3.56 | 4.31 | 3.97 | 3.99 | 3.82 | 4.77 | 4.76 | 4.25 | 4.24 | 2.14 | 1.88 | 2.03 | 1.79 | 11.33 | 11.65 | 11.61 | 11.79 | 1.08 | 0.83 | 0.75 |
ROCE % |
4.50 | 4.62 | 4.51 | 2.89 | 3.79 | 3.45 | 3.35 | 2.84 | 4.41 | 5.08 | 7.33 | 8.46 | 22.12 | 23.36 | 27.96 | 36.00 | 30.01 | 34.88 | 32.95 | 15.21 | 20.13 | 15.25 | 12.59 | 12.86 | 12.43 | 12.73 | 12.88 | 12.53 | 11.79 | 11.81 | 11.36 | 11.81 | 11.73 | 12.16 | 12.37 | 13.34 | 12.96 | 12.69 | 12.32 | 8.36 | 9.86 | 9.45 | 10.06 | 10.32 | 13.48 | 13.51 | 12.12 | 11.42 | 5.17 | 4.49 | 5.04 | 5.08 | 9.21 | 8.84 | 8.29 | 8.58 | 1.86 | 2.01 | 2.17 |
Current Ratio |
2.5 | 2.6 | 2.6 | 2.6 | 2.6 | 2.4 | 2.4 | 2.4 | 2.3 | 2.2 | 2.2 | 2.1 | 2.0 | 2.0 | 1.9 | 1.9 | 1.9 | 1.9 | 1.8 | - | 1.9 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.7 | 1.7 | 1.7 | 1.7 | 2.0 | 2.0 | 2.0 | 1.9 | - | 2.0 | 2.1 | 2.0 | 2.0 | 2.0 | 2.0 | 2.0 | 2.0 | 2.0 | 2.0 | 2.0 | 2.0 | 2.0 | 2.0 | 2.0 | 2.5 | 2.3 | 2.2 | 2.4 |
DSO |
87.6 | 81.0 | 85.8 | - | 80.0 | 78.3 | 85.8 | - | 86.5 | 78.1 | 81.1 | - | 94.4 | 95.5 | 100.4 | 71.6 | 102.8 | 73.2 | 34.1 | - | 71.3 | 75.0 | 95.9 | 83.3 | 93.6 | 91.6 | 95.5 | 76.3 | 85.6 | 82.1 | 84.0 | 78.5 | 90.9 | 92.1 | 85.8 | 68.7 | 78.0 | 74.2 | 40.0 | - | 68.0 | 68.0 | 76.7 | 70.6 | 79.2 | 77.2 | 80.6 | 72.0 | 81.6 | 79.0 | 83.7 | 72.8 | 81.8 | 79.9 | 72.7 | 69.5 | 74.8 | 69.3 | - |
DIO |
108.1 | 107.2 | 118.1 | - | 122.9 | 121.5 | 130.3 | - | 133.5 | 128.8 | 129.8 | - | 150.1 | 168.5 | 143.7 | - | 156.2 | 87.6 | 46.3 | - | 100.8 | 109.0 | 99.4 | - | 89.3 | 86.9 | 93.0 | - | 90.3 | 85.0 | 89.5 | - | 112.5 | 110.9 | 101.6 | - | 104.0 | 99.2 | 54.5 | - | 91.3 | 87.3 | 90.2 | - | 87.2 | 84.5 | 84.5 | - | 82.4 | 79.6 | 82.8 | - | 81.0 | 79.9 | 74.4 | - | 81.1 | 75.6 | - |
DPO |
49.8 | 49.6 | 54.5 | - | 53.6 | 53.4 | 60.0 | - | 64.9 | 74.8 | 83.9 | - | 91.2 | 94.2 | 87.2 | - | 87.0 | 55.8 | 29.6 | - | 53.6 | 61.1 | 62.1 | - | 59.0 | 57.4 | 61.1 | - | 59.0 | 55.5 | 57.5 | - | 71.0 | 70.0 | 60.4 | - | 54.7 | 51.0 | 27.7 | - | 47.3 | 48.1 | 51.9 | - | 53.1 | 51.5 | 52.7 | - | 52.7 | 51.0 | 54.7 | - | 55.3 | 54.5 | 54.0 | - | 54.0 | 50.5 | - |
Operating Cycle |
195.7 | 188.2 | 203.9 | - | 202.9 | 199.8 | 216.1 | - | 220.0 | 207.0 | 210.9 | - | 244.5 | 264.0 | 244.1 | 71.6 | 259.0 | 160.8 | 80.4 | - | 172.1 | 184.1 | 195.3 | 83.3 | 182.9 | 178.5 | 188.6 | 76.3 | 175.9 | 167.1 | 173.4 | 78.5 | 203.4 | 203.0 | 187.5 | 68.7 | 182.0 | 173.4 | 94.5 | - | 159.3 | 155.4 | 166.9 | 70.6 | 166.4 | 161.7 | 165.1 | 72.0 | 164.0 | 158.7 | 166.4 | 72.8 | 162.9 | 159.8 | 147.0 | 69.5 | 155.9 | 144.9 | - |
Cash Conversion Cycle |
145.9 | 138.6 | 149.4 | - | 149.3 | 146.4 | 156.1 | - | 155.1 | 132.2 | 127.0 | - | 153.3 | 169.7 | 156.9 | 71.6 | 172.0 | 105.1 | 50.8 | - | 118.5 | 122.9 | 133.1 | 83.3 | 123.9 | 121.1 | 127.4 | 76.3 | 116.9 | 111.6 | 116.0 | 78.5 | 132.4 | 133.0 | 127.1 | 68.7 | 127.3 | 122.4 | 66.8 | - | 112.0 | 107.3 | 115.1 | 70.6 | 113.3 | 110.2 | 112.4 | 72.0 | 111.3 | 107.7 | 111.8 | 72.8 | 107.6 | 105.3 | 93.0 | 69.5 | 101.9 | 94.5 | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company PerkinElmer, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Diagnostics research industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
$ 0.33 | -6.23 % | $ 30.6 M |  Germany |
 |
Fluidigm Corporation
FLDM
|
$ 3.75 | 1.08 % | $ 308 M |  USA |
 |
Global Cord Blood Corporation
CO
|
$ 2.99 | - | $ 399 M |  China |
 |
Oxford Immunotec Global PLC
OXFD
|
$ 21.99 | - | $ 562 M |  Britain |
 |
Genetron Holdings Limited
GTH
|
$ 4.03 | 0.12 % | $ 80.1 M | China |
 |
Chembio Diagnostics
CEMI
|
$ 0.46 | 0.22 % | $ 16.8 M | USA |
 |
Meridian Bioscience
VIVO
|
$ 33.97 | - | $ 1.49 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
$ 0.48 | -20.0 % | $ 1.06 M | USA |
 |
Quotient Limited
QTNT
|
$ 0.32 | -11.32 % | $ 1.1 M |  Schweiz |
 |
Bioventus
BVS
|
$ 7.41 | 0.34 % | $ 464 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
$ 165.21 | - | $ 10.7 B | USA |
 |
Heska Corporation
HSKA
|
$ 119.99 | - | $ 1.31 B | USA |
 |
Motus GI Holdings
MOTS
|
$ 0.17 | -34.28 % | $ 263 K |  Israel |
 |
Biocept
BIOC
|
$ 0.43 | -13.05 % | $ 7.29 M | USA |
 |
Syneos Health
SYNH
|
$ 42.98 | - | $ 4.46 B | USA |
 |
Invitae Corporation
NVTA
|
$ 0.09 | - | $ 21.2 M | USA |
 |
DermTech
DMTK
|
$ 0.09 | -11.32 % | $ 2.94 M | USA |
|
Akumin
AKU
|
$ 0.29 | -17.87 % | $ 25.9 M |  Canada |
 |
Castle Biosciences
CSTL
|
$ 33.7 | 0.39 % | $ 936 M | USA |
 |
DarioHealth Corp.
DRIO
|
$ 12.58 | -7.4 % | $ 357 M | Israel |
 |
OpGen
OPGN
|
$ 1.96 | -16.95 % | $ 1.54 M | USA |
 |
DexCom
DXCM
|
$ 58.14 | -1.92 % | $ 22.4 B | USA |
 |
Neogen Corporation
NEOG
|
$ 5.98 | -3.78 % | $ 1.3 B | USA |
 |
Organovo Holdings
ONVO
|
$ 2.12 | -2.3 % | $ 19.4 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
$ 12.25 | 0.41 % | $ 133 M | China |
 |
Pacific Biosciences of California
PACB
|
$ 1.78 | -7.03 % | $ 451 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
$ 28.27 | 0.69 % | $ 20 B |  Niderland |
 |
Danaher Corporation
DHR
|
$ 211.38 | -0.39 % | $ 155 B | USA |
 |
Biomerica
BMRA
|
$ 2.55 | -1.16 % | $ 5.86 M | USA |
 |
Fulgent Genetics
FLGT
|
$ 22.23 | -2.41 % | $ 672 M | USA |
 |
Thermo Fisher Scientific
TMO
|
$ 566.14 | -0.28 % | $ 216 B | USA |
 |
Psychemedics Corporation
PMD
|
$ 2.67 | -1.84 % | $ 15.3 M | USA |
 |
Trinity Biotech plc
TRIB
|
$ 0.98 | -1.5 % | $ 61.9 M |  Irlanda |
 |
Genetic Technologies Limited
GENE
|
$ 0.77 | - | $ 7.1 B |  Australia |
 |
Twist Bioscience Corporation
TWST
|
$ 30.5 | -3.24 % | $ 1.77 B | USA |
 |
Myriad Genetics
MYGN
|
$ 6.38 | -3.12 % | $ 578 M | USA |
 |
Renalytix AI plc
RNLX
|
$ 0.21 | 5.66 % | $ 22.7 M | Britain |
 |
Quidel Corporation
QDEL
|
$ 21.75 | -20.55 % | $ 916 M | USA |
 |
Medpace Holdings
MEDP
|
$ 598.15 | -0.11 % | $ 18.5 B | USA |
 |
IQVIA Holdings
IQV
|
$ 212.13 | 0.96 % | $ 38.5 B | USA |
 |
CareDx, Inc
CDNA
|
$ 14.89 | -9.95 % | $ 801 M | USA |
 |
Exagen
XGN
|
$ 10.63 | 2.9 % | $ 188 M | USA |
 |
Brainsway Ltd.
BWAY
|
$ 15.8 | -2.29 % | $ 99.4 M | Israel |
|
Biodesix
BDSX
|
$ 7.84 | -8.84 % | $ 1.02 B | USA |
 |
T2 Biosystems
TTOO
|
$ 0.12 | -39.35 % | $ 313 K | USA |
 |
OPKO Health
OPK
|
$ 1.38 | 2.99 % | $ 958 M | USA |
 |
Guardant Health
GH
|
$ 96.58 | 1.61 % | $ 11.9 B | USA |
 |
Agilent Technologies
A
|
$ 147.55 | 0.53 % | $ 44.9 B | USA |
 |
Co-Diagnostics
CODX
|
$ 0.4 | 0.84 % | $ 11.7 M | USA |